Among adults with overweight or obesity taking tirzepatide, weekly injections of apitegromab at 10 mg/kg reduce the loss of lean body mass by 1.9 kilograms over 24 weeks compared to placebo, without changing total weight loss.
See the scientific wording
In adults with overweight or obesity receiving tirzepatide, weekly administration of apitegromab at 10 mg/kg significantly reduces lean mass loss by 1.9 kg over 24 weeks compared to placebo, while total weight loss remains similar, indicating that selective myostatin inhibition can preserve skeletal muscle during pharmacologic weight loss.
Very strong evidence
Randomized trialsOne high-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
When people took a drug called apitegromab along with tirzepatide, they lost the same amount of total weight as those who took a placebo, but they lost much less muscle—about 1.9 kg less. This means apitegromab helped protect their muscles while they lost fat.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a natural signal that stops muscle growth, so even when the body is losing weight and breaking down tissue, muscles keep their mass because the signal that tells them to shrink is turned off.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Among adults with overweight or obesity taking tirzepatide, weekly injections of apitegromab at 10 mg/kg reduce the loss of lean body mass by 1.9 kilograms over 24 weeks compared to placebo, without changing total weight loss.
Mechanism
1 studyA drug stops a natural brake on muscle growth, so when the body loses weight, muscles don't shrink as much. The muscle stays the same because the signal that tells it to break down is blocked.
A drug blocks a natural signal that stops muscle growth, so even when the body is losing weight and breaking down tissue, muscles keep their mass because the signal that tells them to shrink is turned off.
A monoclonal antibody binds to inactive precursor forms of myostatin in the bloodstream, preventing their conversion into the active protein
Active myostatin is not produced, removing its suppression of satellite cell activation and muscle protein synthesis
Muscle protein breakdown via the ubiquitin-proteasome pathway is reduced due to absence of myostatin signaling
Net muscle protein balance shifts toward accumulation, maintaining skeletal muscle mass despite systemic catabolic pressure from weight-loss pharmacotherapy
Evidence from Studies
Supporting (1)
Community contributions welcome
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
When people took a drug called apitegromab along with tirzepatide, they lost the same amount of total weight as those who took a placebo, but they lost much less muscle—about 1.9 kg less. This means apitegromab helped protect their muscles while they lost fat.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Myostatin Inhibitors on Lean Mass Preservation During Pharmacologic Weight Loss in Adults with Obesity
Population: Adults with overweight or obesity receiving weight-loss pharmacotherapy; Intervention: Apitegromab at 10 mg/kg weekly; Comparator: Placebo; Outcome: Change in lean mass and total weight over 24 weeks; Duration: Minimum 24 weeks
Double-Blind, Placebo-Controlled Trial of Apitegromab 10 mg/kg Weekly on Lean Mass Preservation in Adults with Obesity Receiving Tirzepatide
Population: Adults with overweight or obesity on tirzepatide; Intervention: Apitegromab 10 mg/kg weekly; Comparator: Placebo; Outcome: Change in lean mass (DXA) and total body weight at 24 weeks; Duration: 24 weeks
Prospective Cohort Study of Apitegromab Use and Lean Mass Changes in Adults with Obesity on Tirzepatide
Population: Adults with overweight or obesity initiating tirzepatide with or without apitegromab; Intervention: Apitegromab at 10 mg/kg weekly; Comparator: No apitegromab; Outcome: Lean mass and total weight measured at baseline and 24 weeks; Duration: 24 weeks
In Vitro Analysis of Apitegromab on Myostatin Signaling and Skeletal Muscle Protein Synthesis in Human Myoblasts
Population: Human skeletal muscle myoblasts; Intervention: Apitegromab at 10 mg/kg equivalent concentration; Comparator: Vehicle control; Outcome: Myostatin pathway inhibition and protein synthesis markers; Duration: 72 hours
Animal Model Study of Apitegromab on Lean Mass Preservation During Pharmacologic Weight Loss in Diet-Induced Obese Mice
Population: Diet-induced obese mice; Intervention: Apitegromab at 10 mg/kg weekly; Comparator: Vehicle; Outcome: Lean mass (MRI) and total body weight over 24 weeks; Duration: 24 weeks